Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Jeff Trent"'
Autor:
Tim F Cloughesy, Koji Yoshimoto, Phioanh Nghiemphu, Kevin Brown, Julie Dang, Shaojun Zhu, Teli Hsueh, Yinan Chen, Wei Wang, David Youngkin, Linda Liau, Neil Martin, Don Becker, Marvin Bergsneider, Albert Lai, Richard Green, Tom Oglesby, Michael Koleto, Jeff Trent, Steve Horvath, Paul S Mischel, Ingo K Mellinghoff, Charles L Sawyers
Publikováno v:
PLoS Medicine, Vol 5, Iss 1, p e8 (2008)
There is much discussion in the cancer drug development community about how to incorporate molecular tools into early-stage clinical trials to assess target modulation, measure anti-tumor activity, and enrich the clinical trial population for patient
Externí odkaz:
https://doaj.org/article/6c668f88ea25476fae7fe61ad50c3162
Autor:
Nazli Dizman, Luis Meza, Paulo Bergerot, Marice Alcantara, Tanya Dorff, Yung Lyou, Paul Frankel, Yujie Cui, Valerie Mira, Marian Llamas, Joann Hsu, Zeynep Zengin, Nicholas Salgia, Sabrina Salgia, Jasnoor Malhotra, Neal Chawla, Alex Chehrazi-Raffle, Ramya Muddasani, John Gillece, Lauren Reining, Jeff Trent, Motomichi Takahashi, Kentaro Oka, Seiya Higashi, Marcin Kortylewski, Sarah K. Highlander, Sumanta K. Pal
Publikováno v:
Nature medicine. 28(4)
Previous studies have suggested that the gut microbiome influences the response to checkpoint inhibitors (CPIs) in patients with cancer. CBM588 is a bifidogenic live bacterial product that we postulated could augment CPI response through modulation o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3378fa6e57d09b2c6e662de7b7528b79
https://pubmed.ncbi.nlm.nih.gov/35899808
https://pubmed.ncbi.nlm.nih.gov/35899808
Autor:
Anton Granzhan, Julia Newton-Bishop, Nicholas K. Hayward, Tongwu Zhang, Jiyoun Choi, Hemang Parikh, Stuart MacGregor, Matthew Law, Kevin M. Brown, Michael A. Kovacs, Mark M. Iles, Matthew M. Makowski, Mai Xu, Kim Wj, Marie-Paule Teulade-Fichou, Michael Gartside, D T Bishop, Michiel Vermeulen, Jeff Trent
Publikováno v:
Nature Genetics, 49, 1326-1339
Nature Genetics, 49, 9, pp. 1326-1339
Nature Genetics, 49, 9, pp. 1326-1339
Previous genome-wide association studies have identified a melanoma-associated locus at 1q42.1 that encompasses a ∼100-kb region spanning the PARP1 gene. Expression quantitative trait locus (eQTL) analysis in multiple cell types of the melanocytic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7d103d23d1c8f884c982e9bad86ecf5
http://hdl.handle.net/2066/177722
http://hdl.handle.net/2066/177722
Autor:
Anne-Marie Gerdes, Richard A. Scolyer, Nicholas K. Hayward, Annalisa Solinas, Klaus J. Busam, B. Federspiel, Hensin Tsao, Antonia L. Pritchard, Ruta Gupta, Peter Johansson, John F. Thompson, Oana Crainic, Lauren G. Aoude, Jason Madore, Annabel Goodwin, Karin Wadt, Kevin M. Brown, Jens Folke Kiilgaard, Morten Andersen, Lone Sunde, Göran Jönsson, Steffen Heegaard, Jeff Trent, Stanley W. McCarthy
Publikováno v:
Clinical Genetics. 88:267-272
We report four previously undescribed families with germline BRCA1-associated protein-1 gene (BAP1) mutations and expand the clinical phenotype of this tumor syndrome. The tumor spectrum in these families is predominantly uveal malignant melanoma (UM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ab2eee1b36c5f8f31ce111fb1827523c
https://doi.org/10.1111/cge.12501
https://doi.org/10.1111/cge.12501
Autor:
Janine LoBello, Yang Mao, Glen J. Weiss, Robert Dagil, Jeff Trent, Jo Soden, Ladan Fazli, Jim Freeth, Bradley John Hedberg, Chris K. Wang, Sherry Lee, Adam F. Sander, John Babcook, Makoto Endo, Francesco Favero, Jamie R. Rich, Peter Johannes Holst, Joseph Zaia, Morten Nielsen, Madeleine Dahlbäck, Poul H. Sorensen, Nhan L. Tran, Marina Ayres Pereira, Tobias Gustavsson, Line Barington, Torsten O. Nielsen, Thomas Mandel Clausen, Ali Salanti, Htoo Zarni Oo, Le Meng, Mette Ø. Agerbæk, Nader Al Nakouzi, Mads Daugaard, Thor G. Theander, Susan Thrane
Publikováno v:
Cancer cell. 28(4)
SummaryPlasmodium falciparum engineer infected erythrocytes to present the malarial protein, VAR2CSA, which binds a distinct type chondroitin sulfate (CS) exclusively expressed in the placenta. Here, we show that the same CS modification is present o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4695c6eacc6e5118f4581629fe39b5e1
https://pubmed.ncbi.nlm.nih.gov/26461094
https://pubmed.ncbi.nlm.nih.gov/26461094
Publikováno v:
Cancer Causes & Control. 17:229-237
To provide the voice of experience to investigators contemplating engagement in the realm of “team science”. Leaders were brought together from academia, government, and industry to share perspectives and insights based on real-life experiences.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::227ba243118358cc53557d9cfc2578d0
https://doi.org/10.1007/s10552-005-0546-5
https://doi.org/10.1007/s10552-005-0546-5
Autor:
Stuart MacGregor, Helen Schmid, Lauren G. Aoude, Judith Symmons, David Youngkin, Kevin M. Brown, Sonika Tyagi, Graham J. Mann, Susan L. Woods, Nicholas K. Hayward, Vanessa F. Bonazzi, K Holohan, Richard F. Kefford, Bruce K. Armstrong, Jane M. Palmer, Jeff Trent, Grant W. Montgomery, N. G. Martin, Ken Dutton-Regester, G Giles, John W Kelly, John L. Hopper, Ji Liu, E Gillanders, Mitchell S. Stark, J Aitken, Michael Gartside, Elizabeth A. Holland, David C. Whiteman, Christopher W. Schmidt, David L. Duffy, Chantelle Agha-Hamilton, Mark A. Jenkins, Anne E. Cust
Publikováno v:
Europe PubMed Central
Hereditary Cancer in Clinical Practice, Vol 10, Iss Suppl 2, p A46 (2012)
Hereditary Cancer in Clinical Practice
Hereditary Cancer in Clinical Practice, Vol 10, Iss Suppl 2, p A46 (2012)
Hereditary Cancer in Clinical Practice
Family and twin studies indicate that melanoma susceptibility has a strong genetic component. Very rarely, melanoma runs in families in which there is an inherited mutation in a single ‘high penetrance’ gene, but in the general population melanom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ce14cfafe6ad071086a3c60aeb0f207
https://doi.org/10.1186/1897-4287-10-s2-a46
https://doi.org/10.1186/1897-4287-10-s2-a46
Autor:
P. Leif Bergsagel, Joan Levy, Andrey Sivachenko, A. Keith Stewart, Suzanne Trudel, Eric S. Lander, Ravi Vij, Rafael Fonseca, Gregory J. Ahmann, Jeff Trent, Angela Baker, Christina L. Harview, Ted Liefeld, Robb Onofrio, Alex H. Ramos, Mazhar Adli, John D. Carpten, Jean Philippe Brunet, Andrzej Jakubowiak, Stacey Gabriel, Wendy Winckler, Jonathan J Keats, Levi A. Garraway, S. Vincent Rajkumar, Sagar Lonial, Matthew Meyerson, Scott Mahan, Amrita Krishnan, David S. Siegel, Carrie Sougnez, Daniel Auclair, Gad Getz, Kristian Cibulskis, Douglas Voet, William C. Hahn, Michael S. Lawrence, Sundar Jagannath, Bunmi Mfuko, Todd R. Golub, Stefano Monti, Kenneth C. Anderson, Craig C. Hofmeister, Yotam Drier, Louise M. Perkins, Anna C. Schinzel, Bradley E. Bernstein, Kristin G. Ardlie, Trevor J. Pugh, Todd Zimmerman, Michael A Chapman
Publikováno v:
Nature
PMC
PMC
Multiple myeloma is an incurable malignancy of plasma cells, and its pathogenesis is poorly understood. Here we report the massively parallel sequencing of 38 tumour genomes and their comparison to matched normal DNAs. Several new and unexpected onco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d634bec2f2694dc3a6244e8956c1c0e
https://pubmed.ncbi.nlm.nih.gov/21508965
https://pubmed.ncbi.nlm.nih.gov/21508965
Autor:
Teli Hsueh, Tom Oglesby, Koji Yoshimoto, Charles L. Sawyers, Michael Koleto, Paul S. Mischel, Don Becker, Marvin Bergsneider, Steve Horvath, Yinan Chen, Jeff Trent, David Youngkin, Neil A. Martin, Julie Dang, Shaojun Zhu, Wei-wei Wang, Linda M. Liau, Timothy F. Cloughesy, Kevin M. Brown, Albert Lai, Richard M. Green, Phioanh L. Nghiemphu, Ingo K. Mellinghoff
Publikováno v:
PLoS Medicine, Vol 5, Iss 1, p e8 (2008)
PLoS Medicine
PLoS Medicine
There is much discussion in the cancer drug development community about how to incorporate molecular tools into early-stage clinical trials to assess target modulation, measure anti-tumor activity, and enrich the clinical trial population for patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4217352ebb06379073eadc22e5259a6c
http://europepmc.org/articles/PMC2211560
http://europepmc.org/articles/PMC2211560
Autor:
Deanna Mitchell, Jeff Trent, Jessica Foley, Abhinav Nagulapally, Jason J. Corneveaux, Matthew Huntelman, Albert Cornelius, Jeff Bond, Giselle Saulnier Sholler
Publikováno v:
Molecular Cancer Therapeutics. 14:B01-B01
Background: Choroid plexus tumors comprise 10-20% of intracranial tumors in children less than one year of age, the majority of these are benign papillomas, however some are highly aggressive carcinomas. Choroid Plexus Carcinoma (CPC) is derived from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12b0d62b6ad40da977e013ecdee1fb38
https://doi.org/10.1158/1538-8514.pi3k14-b01
https://doi.org/10.1158/1538-8514.pi3k14-b01